GRIFOLS SA

ISIN: ES0171996087 WKN: - Asset Class: Stock



Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Financial figures, Fiscal year: from 01.01. to 31.12.								
Financial figures	2023 Assets Liabilities and equity		2022 Assets Liabilities and equity		2021 Assets Liabilities and equity			
Current assets	6,451,905,000		4,653,587,000		5,510,280,000			
Common stock capital		119,604,000		119,604,000		119,604,000		
Fixed assets	15,002,765,000		17,007,730,000		13,801,384,000			
Equity capital of a company		7,972,485,000		8,457,544,000		8,147,035,000		
Cash and cash equivalents	529,577,000		547,979,000		655,493,000			
Accrued liabilities		116,925,000		110,063,000		24,122,000		
Other assets	-		-		-			
Current liabilities		2,315,604,000		1,955,847,000		3,474,312,000		
Prepayments and accrued income	-		-		-			
Non-current liabilities		11,152,774,000		11,232,803,000		7,675,281,000		
Different income		-		-		-		
Other liabilities		814,080,000		891,725,000		9,222,000		
Total assets	21,454,670,000	21,454,670,000	21,661,317,000	21,661,317,000	19,311,664,000	19,311,664,000		

	1 1 1		1 1 1		
	-		-		-
	814,080,000		891,725,000		9,222,000
21,454,670,000	21,454,670,000	21,661,317,000	21,661,317,000	19,311,664,000	19,311,664,000
			2023	2022	2021
			IFRS	IFRS	IFRS
			23,744	26,326	23,245
			47.16%	49.79%	52.80%
			112.05%	100.84%	89.38%
			2023	2022	2021
			26.89%	34.76%	29.90%
	21,454,670,000		· · ·	21,454,670,000 21,454,670,000 21,661,317,000 21,661,317,000 2023 IFRS 23,744 47.16% 112.05%	21,454,670,000 21,454,670,000 21,661,317,000 21,661,317,000 19,311,664,000 2023 2022 IFRS IFRS 23,744 26,326 47.16% 49.79% 112.05% 100.84% 2023 2022

GRIFOLS SA

ISIN: ES0171996087 WKN: - Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	6,591,977,000	6,063,967,000	4,933,118,000
Net income	59,315,000	208,279,000	182,803,000
EBIT	732,630,000	747,110,000	569,789,000
Operating income before taxes	161,200,000	259,261,000	284,710,000
Cash Flow	208,283,000	-150,000	608,423,000
Net interest income	-571,430,000	-487,849,000	-285,079,000
Research and development expenses	330,551,000	316,845,000	299,570,000
Income taxes	43,349,000	90,111,000	85,126,000
Result from investments in subsidaries, associates and other	62,818,000	101,996,000	65,743,000
Revenues per employee	277,627	230,341	212,223

Board of Directors	
T	
Thomas Heinrich Glanzmann	Chairman of Supervisory Board
Enriqueta Felip Font	Member of Supervisory Board
Albert Coma-Cros	Member of Supervisory Board
Anne-Catherine Berner	Member of Supervisory Board
Carina Szpilka Lázaro	Member of Supervisory Board
Claire Giraut	Member of Supervisory Board
James Costos	Member of Supervisory Board
Montserrat Muñoz Abellana	Member of Supervisory Board
Susana González Rodríguez	Member of Supervisory Board
Tomás Dagá Gelabert	Member of Supervisory Board
Íñigo Sánchez-Asiaín Mardones	Member of Supervisory Board

Members of Management Board				
The man Oleman and	Obsimus of Managing Based			
Thomas Glanzmann	Chairman of Managing Board			
Raimon Grifols Roura	Member of Executive Committee			
Víctor Grífols Deu	Member of Executive Committee			